Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals
Established SENS Research Foundation in 2009 with Aubrey de Grey, and was its founding CEO, serving until 2019.
Received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; Director of Corporate Development for Aviron/MedImmune, Inc.; and as CEO and officer of a number of biotechnology startups.
Visit website: https://underdogpharma.com/team/#kope
See also: Cyclarity Therapeutics - Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.
Mentioned in this Resource
Michael Kope is also referenced in the following:
Michael Kope News
Reason reports back from October's Rejuvenation Startup Summit
Fight Aging! - 19-Oct-2022
Some really exciting developments with quite a few in clinical trialsRead more...
Racing for the lead... Underdog becomes Cyclarity Therapeutics
Longevity Technology - 20-Jun-2022
Also announces move to Buck Institute for Research on AgingRead more...
Underdog pharmaceuticals secures $10m funding from Kizoo ventures
Longevity Technology - 23-Sep-2021
Funds to bring affordable and effective age-related therapies to the publicRead more...